NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

ReVance Therapeutics, Inc. 

2400 Bayshore Parkway, Suite 100

Mountain View  California  94043  U.S.A.
Phone: n/a Fax:


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
Medicis (MRX) and ReVance Therapeutics, Inc. Announce Agreement for Development of Next-Gen Neurotoxin; Revance to Receive $10M and Additional Milestone Payments of $94M 7/29/2009 7:34:06 AM    More...
ReVance Therapeutics, Inc. Levers Up with $8 Million Financing 11/18/2008 8:11:52 AM    More...
ReVance Therapeutics, Inc. Announces Additional $8M Series C Expansion 5/12/2008 10:13:26 AM    More...
Medicis (MRX) and ReVance Therapeutics, Inc. Announce Strategic Collaboration 12/12/2007 8:52:34 AM    More...
ReVance Therapeutics, Inc. Announces Initiation Of Phase Ib Clinical Trial Of Topically Applied Botulinum Toxin Type A Gel For The Treatment Of Facial Aesthetics 11/9/2006 11:37:49 AM    More...
ReVance Therapeutics, Inc. Announces Management Additions; Company Strengthens Clinical, Regulatory And R&D Capabilities 10/19/2005 5:09:19 PM    More...